Section
This review synthesizes cutting-edge findings on how genetic and nongenetic RAS-pathway activation mediates resistance to combined FLT3 and BCL2 inhibition in acute myeloid leukemia, highlighting implications for treatment strategies and bi
This study identifies plasma proteomic signatures linked to clonal hematopoiesis driver mutations and develops a proteomic risk score that independently predicts adverse clinical outcomes in heart failure with preserved ejection fraction (H
A large Spanish study reveals the shifting landscape of GVHD prophylaxis in alloHSCT, highlighting widespread post-transplant cyclophosphamide use and its impact on acute and chronic GVHD incidence and survival outcomes.
T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy’s
Maintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.
This study clinically validates an AI-based quantitative tool, CIF, for bone marrow fibrosis assessment, demonstrating improved reproducibility and accuracy over manual grading without increasing assessment time.
This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival
PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.
The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid ma
A large retrospective study demonstrates that transfusion of low-titer group O whole blood (LTOWB) in trauma resuscitation carries a low and comparable risk of early red blood cell alloimmunization relative to component therapy, including a
This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.
This study identifies neutrophil-dependent type-I interferon responses and NETs as key drivers of joint damage in hemophilia A, opening avenues for novel therapies to prevent hemophilic arthropathy.
Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamic
A multicenter retrospective study of 1047 AL amyloidosis patients undergoing autologous stem cell transplantation (2010–2020) demonstrates improved safety, deep hematologic responses, and durable survival, affirming ASCT’s vital role in tre
This review analyzes the impact of age and anthracycline-based chemotherapy on mortality in 28,000 classic Hodgkin lymphoma patients, highlighting poorer outcomes in the elderly and the therapeutic nuances influencing survival.
This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive the
This study identifies systemic pathological pathways that mediate blood-brain barrier injury in sickle cell disease, linking BBB disruption to brain hypoxia and microstructural injury, highlighting new therapeutic targets to preserve neurol
This study reveals that integrin αIIbβ3 deficiency in megakaryocytes disrupts serine metabolism, leading to reduced platelet production and shedding light on the complex pathophysiology underlying Glanzmann thrombasthenia.
Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori
A retrospective study demonstrates the safety and efficacy of GCSF and plerixafor for CD34+ stem cell mobilization as autologous backup in sickle cell patients undergoing alternate donor HSCT, with insights relevant for gene therapy.
